Home/Pipeline/FT819

FT819

B-cell Malignancies

Phase 1Active

Key Facts

Indication

B-cell Malignancies

Phase

Phase 1

Status

Active

Company

Fate Therapeutics

About Fate Therapeutics

Fate Therapeutics is dedicated to transforming patient lives with autoimmune diseases and cancer through its proprietary iPSC platform, which generates 'off-the-shelf' cell therapies. The company's mission is to make cell therapy delivery routine and accessible by developing multiplexed-engineered cell product candidates that incorporate novel synthetic controls of cell function. Its pipeline includes several clinical-stage candidates, such as FT819, FT825, FT836, FT839, and FT522, targeting both oncology and autoimmune indications. Fate operates as a public company, leveraging strategic collaborations to advance its science and clinical development.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Mezagitamab	Kyowa Kirin	Phase 1/2	Active
Velexbru (tirabrutinib)	Ono Pharmaceutical	Phase 3	Active
KT-413	Kymera Therapeutics	Phase 1	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
HMPL-760	HUTCHMED	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied